DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

* Participant has provided informed consent before initiation of any study-specific activities/procedures.

* Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.

* Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC [T any, N any, M1 a/b/c]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan.

* Measurable disease as defined per RECIST 1.1.

* Suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment per investigator clinical assessment.

* Minimum life expectancy ≥ 12 weeks.

* Participants can have no history of other malignancy in the last 2 years.

* Any symptomatic central nervous system (CNS) metastases, or leptomeningeal disease.

* They will have no history of severe or life-threatening events to immune-mediated therapy.

* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.

* They will have no active autoimmune or inflammatory disorders.

* Presence of active human immunodeficiency virus (HIV) or active Hepatitis (B/C) infection.

* Evidence or interstitial lung disease (ILD) or active, non-infectious pneumonitis.

* History of solid organ transplant.

* They will not have had a myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 6 months prior to first dose of study treatment.